Free tool
FAERS Monitor: Lodosyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017830 or its brand name (Lodosyn, Carbidopa). Reports on generic versions are filed under their own applications.
Reports
3,125
Serious
1,919
61% of reports
Hospitalization
933
Death reported
477
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hallucination306
- drug ineffective292
- fall255
- death254
- fatigue202
- nausea202
- dizziness198
- parkinson^s disease180
- confusional state154
- tremor137
- condition aggravated134
- somnolence128
- gait disturbance127
- asthenia122
- product dose omission issue119
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 26 |
| 2006 | 37 |
| 2007 | 38 |
| 2008 | 42 |
| 2009 | 50 |
| 2010 | 57 |
| 2011 | 62 |
| 2012 | 74 |
| 2013 | 58 |
| 2014 | 85 |
| 2015 | 141 |
| 2016 | 158 |
| 2017 | 273 |
| 2018 | 305 |
| 2019 | 266 |
| 2020 | 243 |
| 2021 | 235 |
| 2022 | 189 |
| 2023 | 184 |
| 2024 | 181 |
| 2025 | 260 |
| 2026 | 144 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hallucinationSignal | 306 | 27.4 | 24.7 | 7,764 |
| confusional stateSignal | 154 | 6.4 | 5.5 | 704 |
| tremorSignal | 137 | 5.6 | 4.7 | 511 |
| fallSignal | 255 | 5.2 | 4.6 | 864 |
| gait disturbanceSignal | 127 | 4.5 | 3.8 | 341 |
| somnolenceSignal | 128 | 4.3 | 3.6 | 321 |
| condition aggravatedSignal | 134 | 3.0 | 2.5 | 175 |
| product dose omission issueSignal | 119 | 2.7 | 2.3 | 130 |
| dizzinessSignal | 198 | 2.7 | 2.3 | 210 |
| astheniaSignal | 122 | 2.2 | 1.8 | 79 |
| death | 254 | 2.0 | 1.8 | 128 |
| fatigue | 202 | 1.7 | 1.5 | 66 |
| nausea | 202 | 1.7 | 1.5 | 62 |
| drug ineffective | 292 | 1.5 | 1.3 | 50 |
| parkinson^s disease | 180 | 0.0 | 0.0 | 1,205,822 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.